J. Kuti

发表

Determination of Tissue Penetration and Pharmacokinetics of Linezolid in Patients with Diabetic Foot Infections Using In Vivo Microdialysis

D. Nicolau, D. Wiskirchen, Ashley K. Shepard, 2011, Antimicrobial Agents and Chemotherapy.

Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo Microdialysis

Christina A. Sutherland, D. Nicolau, D. Wiskirchen, 2010, Antimicrobial Agents and Chemotherapy.

In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers

Christina A. Sutherland, D. Nicolau, Aryun Kim, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Evaluation of Meropenem and Cefotaxime for Pediatric Meningitis

D. Nicolau, J. Kuti, J. Ellis, 2006, Paediatric drugs.

Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.

D. Nicolau, J. Kuti, E. Ludwig, 2006, International journal of antimicrobial agents.

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.

R. Masterton, D. Nicolau, P. Turner, 2005, The Journal of antimicrobial chemotherapy.

Derivation of Meropenem Dosage in Patients Receiving Continuous Veno-Venous Hemofiltration Based on Pharmacodynamic Target Attainment

D. Nicolau, J. Kuti, 2005, Chemotherapy.

Making the most of surveillance studies: summary of the OPTAMA Program.

D. Nicolau, J. Kuti, 2005, Diagnostic microbiology and infectious disease.

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.

G. Drusano, D. Nicolau, J. Kuti, 2004, Clinical therapeutics.

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

D. Nicolau, C. Mendes, C. Kiffer, 2004, Diagnostic microbiology and infectious disease.

Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

D. Nicolau, C. Nightingale, J. Kuti, 2004, Pharmacotherapy.

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, Diagnostic microbiology and infectious disease.

A New Progestin Implant (Implanon) for Long-Term Contraception

D. Nicolau, Charles H. Nightingale, David P. Nicolau, 2007 .

Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.

D. Nicolau, C. Mendes, C. Kiffer, 2006, International journal of antimicrobial agents.

Pharmacodynamic Comparison of the Carbapenems Against E. coli and Klebsiella spp. Containing Extended spectrum β-lactamases

D. Nicolau, J. Kuti, K. Eagye, 2005 .

Implementing a Continuous or Prolonged Infusion Beta-Lactam Program in the Hospital Setting

M. Scheetz, S. MacVane, J. Kuti, 2016 .

Divergence in MIC Distributions of Pseudomonas aeruginosa for Piperacillin and Piperacillin/Tazobactam

J. Kuti, 2001 .

Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia

J. Kuti, J. Cies, J. Jain, 2015, Pediatric blood & cancer.

Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young Children

J. Kuti, J. Cies, V. Shankar, 2014, The Pediatric infectious disease journal.

Inappropriate Antibiotic Use Due to Decreased Compliance with a Ventilator‐Associated Pneumonia Computerized Clinical Pathway: Implications for Continuing Education and Prospective Feedback

D. Nicolau, M. Nailor, J. Kuti, 2012, Pharmacotherapy.

Length of Stay and Hospital Costs Associated with a Pharmacodynamic‐Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator‐Associated Pneumonia

D. Nicolau, J. Kuti, K. Eagye, 2010, Pharmacotherapy.

Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.

D. Nicolau, M. Monogue, J. Kuti, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure

D. Nicolau, A. Thabit, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus

D. Nicolau, S. MacVane, J. Kuti, 2014, Antimicrobial Agents and Chemotherapy.

Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant 5

D. Nicolau, S. MacVane, J. Kuti, 2014 .

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

D. Nicolau, E. Salerno, J. Kuti, 2012, Antimicrobial Agents and Chemotherapy.

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.

L. Santos Filho, D. Nicolau, J. Kuti, 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Infection and Antibiotic Agents in Bleeding Trauma Patients: A Review of Available Literature.

J. Kuti, Janel Keating, L. Jacobs, 2022, Surgical infections.

Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation

D. Nicolau, J. Kuti, R. Pettit, 2019, Antimicrobial Agents and Chemotherapy.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department

D. Nicolau, K. Keyloun, M. Nailor, 2018, BMC Health Services Research.

Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles

J. Quinn, D. Nicolau, K. Lolans, 2008, Infection and drug resistance.

In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth

D. Nicolau, J. Kuti, Maxwell J. Lasko, 2022, Antimicrobial agents and chemotherapy.

Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.

J. D. De Waele, M. Rizk, Elizabeth G. Rhee, 2021, International journal of antimicrobial agents.

Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms

D. Nicolau, J. Kuti, A. Kois, 2020, Current opinion in infectious diseases.

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

D. Nicolau, Qi Wang, Hui Wang, 2018, Infection and drug resistance.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

C. Arias, M. Weisser, D. Nicolau, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers

D. Nicolau, M. Monogue, Ashley K. Shepard, 2017, Antimicrobial Agents and Chemotherapy.

Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles

D. Nicolau, J. Kuti, J. Aslanzadeh, 2017, Journal of Clinical Microbiology.

Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory

D. Nicolau, J. Kuti, M. Grupper, 2016, Clinical Microbiology Reviews.

Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis

D. Nicolau, M. Monogue, Ashley K. Shepard, 2017, Antimicrobial Agents and Chemotherapy.

The Principles of Pharmacoeconomics

C. Coleman, J. Kuti, E. Kuti, 2007 .

Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.

D. Nicolau, S. Kotapati, C. Nightingale, 2005, The Journal of infection.

Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection

Islam M. Ghazi, D. Nicolau, M. Nailor, 2016, Infection Control & Hospital Epidemiology.

Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients

D. Nicolau, C. Nightingale, Chonghua Li, 2006, Journal of clinical pharmacology.

Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation.

D. Nicolau, O. Serrano, J. Kuti, 2021, Surgical infections.

Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5‐Minute Infusion versus the Standard 30‐Minute Infusion in Healthy Adult Volunteers

D. Nicolau, R. Quintiliani, D. Wiskirchen, 2013, Pharmacotherapy.

Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.

D. Nicolau, J. Kuti, Heather K Sun, 2006, Chest.

Pharmacodynamic Target Attainment of Six β‐Lactams and Two Fluoroquinolones Against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive Care Units in 2004

D. Nicolau, J. Kuti, C. DeRyke, 2007, Pharmacotherapy.

Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.

D. Nicolau, J. Kuti, P. Kontou, 2009, The American journal of emergency medicine.

Cost Considerations in the Use of Antibiotics for the Treatment of Community-Acquired Respiratory Tract Infections

J. Kuti, 2003 .

Optimization of meropenem dosage in the critically ill population based on renal function

R. Ariano, D. Nicolau, J. Crandon, 2011, Intensive Care Medicine.

Time Required by Pharmacy Technicians to Reconstitute New versus Old Piperacillin/Tazobactam Formulations

D. Nicolau, J. Kuti, J. Sahni, 2007 .

Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.

D. Nicolau, J. Kuti, S. Housman, 2011, Clinics in chest medicine.

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.

D. Nicolau, M. Palter, J. Kuti, 2010, Journal of critical care.

Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem

D. Nicolau, J. Kuti, Anthony M. Nicasio, 2009 .

Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery

D. Nicolau, J. Kuti, L. Maggio, 2017, Journal of clinical pharmacology.

Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone Concentrations

D. Nicolau, J. Kuti, I. Chen, 2019, Journal of Clinical Microbiology.

Pharmacodynamics of antimicrobials: treatment optimisation

D. Nicolau, J. Kuti, E. L. Gillespie, 2005, Expert opinion on drug metabolism & toxicology.

Critique of prevention of pneumococcal disease in high risk adults: A pharmacist‐based assessment of adult immunization protocols in clinical practice

D. Nicolau, J. Kuti, 2019, Journal of the American College of Clinical Pharmacy.

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM

J. Kuti, 2016 .

Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

D. Nicolau, J. Kuti, Somvadee Laohavaleeson, 2007, Expert opinion on investigational drugs.

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)

D. Nicolau, Aryun Kim, J. Kuti, 2019, Infectious Diseases and Therapy.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation

D. Nicolau, M. Monogue, M. Muhlebach, 2016, Antimicrobial Agents and Chemotherapy.

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

M. Neely, D. Nicolau, M. Scheetz, 2016, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

M. Neely, D. Nicolau, Jiajun Liu, 2015, Antimicrobial Agents and Chemotherapy.

Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.

Y. Hamada, D. Nicolau, J. Kuti, 2015, The Journal of antimicrobial chemotherapy.

Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections ( cSSTI )

D. Nicolau, J. Kuti, Wonhee So, 2014 .

Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.

D. Nicolau, M. Dowzicky, J. Kuti, 2007, Clinical therapeutics.

Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.

D. Nicolau, J. Kuti, K. Eagye, 2007, Surgical infections.

In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

D. Nicolau, J. Kuti, S. Housman, 2013, Antimicrobial Agents and Chemotherapy.

Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosa

D. Nicolau, J. Kuti, K. Eagye, 2009, Infection Control & Hospital Epidemiology.

Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults

D. Nicolau, P. Crownover, J. Crandon, 2009, Antimicrobial Agents and Chemotherapy.

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.

D. Nicolau, S. Kotapati, C. Nightingale, 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.

D. Nicolau, C. Nightingale, J. Kuti, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

L. Saiman, D. Nicolau, N. Neu, 2018, Diagnostic microbiology and infectious disease.

Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function

D. Nicolau, A. Thabit, J. Kuti, 2017, Journal of pharmacy practice.

Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection

K. Itani, D. Mercer, D. Nicolau, 2006, Antimicrobial Agents and Chemotherapy.

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019 .

Antimicrobial Stewardship at Transitions of Care to Outpatient Settings: Synopsis and Strategies

J. Kuti, E. Liu, Kristin E. Linder, 2022, Antibiotics.

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.

C. Gomersall, D. Nicolau, J. Roberts, 2011, International journal of antimicrobial agents.

Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

J. Kuti, E. Kuti, 2010, Expert opinion on drug metabolism & toxicology.

Changes in Pharmacodynamic Target Attainment for Antimicrobials Over a 2-Year Period: Results of the 2004 OPTAMA Program in North America

D. Nicolau, J. Kuti, C. DeRyke, 2007 .

Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults

D. Nicolau, P. Papasavas, J. Kuti, 2012, Antimicrobial Agents and Chemotherapy.

Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species

Bo Zhang, Christina A. Sutherland, D. Nicolau, 2006, Antimicrobial Agents and Chemotherapy.

Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, Pharmacotherapy.

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

D. Nicolau, J. Kuti, C. DeRyke, 2007, Diagnostic microbiology and infectious disease.

Empiric Pharmacodynamic Performance of 9 Antimicrobials Against Pathogens Implicated in the Cause of Complicated Skin and Soft Tissue Infections: A Report From the OPTAMA Program

D. Nicolau, S. Y. Lee, J. Kuti, 2006 .

Klebsiella pneumoniae by Various Testing Methods 5

S. Jenkins, D. Nicolau, J. Vincent, 2010 .

Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for other Enterococcal species by the Clinical and Laboratory Standards Institute.

M. Weinstein, R. Humphries, J. Jorgensen, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae

D. Nicolau, J. Kuti, S. A. Almarzoky Abuhussain, 2018, Antimicrobial Agents and Chemotherapy.

Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.

D. Nicolau, J. Kuti, I. Chen, 2020, Clinical therapeutics.

Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections

D. Nicolau, Chonghua Li, J. Kuti, 2007, Antimicrobial Agents and Chemotherapy.

A guide to therapeutic drug monitoring of β‐lactam antibiotics

D. Nicolau, J. Kuti, A. Fratoni, 2021, Pharmacotherapy.

Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria

D. Nicolau, J. Kuti, James M. Kidd, 2018, Expert opinion on pharmacotherapy.

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.

D. Nicolau, Aryun Kim, J. Kuti, 2009, Clinical therapeutics.

Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.

D. Nicolau, J. Kuti, John W. Mah, 2022, The Journal of antimicrobial chemotherapy.

Comparative Efﬁcacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model (cid:1)

D. Nicolau, J. Crandon, J. Kuti, 2010 .

Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

D. Nicolau, Aryun Kim, J. Kuti, 2011, Mycoses.

Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers

D. Nicolau, J. Kuti, P. Tessier, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – A review of 3 cases

D. Nicolau, R. Quintiliani, J. Kuti, 2010 .

Inhaled antimicrobial therapies for respiratory infections

D. Nicolau, S. Kim, J. Kuti, 2008, Current infectious disease reports.

Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Antimicrobial Agents and Chemotherapy.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Michael N Neely, Jason A Roberts, Jerome J. Schentag, 2014, The Lancet. Infectious diseases.

Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.

L. Saiman, D. Nicolau, N. Neu, 2016, The Journal of antimicrobial chemotherapy.

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

D. Nicolau, J. Crandon, J. Kuti, 2009, Antimicrobial Agents and Chemotherapy.

Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.

D. Nicolau, S. Y. Lee, J. Kuti, 2007, Journal of Infection.

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

D. Nicolau, Aryun Kim, J. Kuti, 2007, Expert opinion on investigational drugs.

In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus

D. Nicolau, D. Wiskirchen, J. Kuti, 2011, Antimicrobial Agents and Chemotherapy.

Developing quality measures for sepsis care in the ICU.

P. Pronovost, S. Berenholtz, P. Barie, 2007, Joint Commission journal on quality and patient safety.

Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections

P. Williams, D. Nicolau, S. Kotapati, 2012, PharmacoEconomics.

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.

D. Nicolau, S. Y. Lee, J. Kuti, 2005, Surgical infections.

Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002

D. Nicolau, C. Nightingale, J. Kuti, 2004, Antimicrobial Agents and Chemotherapy.

Performance of the PIRO Score for Predicting Mortality in Patients with Ventilator-Associated Pneumonia

D. Nicolau, D. Wiskirchen, G. Furtado, 2012, Anaesthesia and intensive care.

Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.

D. Nicolau, J. Kuti, J. Ellis, 2005, Clinical therapeutics.

Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections

J. Kuti, Kristin E. Linder, A. Bilinskaya, 2020, Expert review of anti-infective therapy.

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Clinical therapeutics.

In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

D. Nicolau, J. Kuti, S. Housman, 2013, The Journal of antimicrobial chemotherapy.

In Vitro Pharmacodynamics of Simulated Pulmonary Exposures of Tigecycline Alone and in Combination against Klebsiella pneumoniae Isolates Producing a KPC Carbapenemase

D. Nicolau, D. Wiskirchen, J. Kuti, 2011, Antimicrobial Agents and Chemotherapy.

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

D. Nicolau, Joseph L Kuti, Charles H Nightingale, 2003, Journal of clinical pharmacology.

Intra-abdominal infections: considerations for the use of the carbapenems

D. Nicolau, I. Kioumis, J. Kuti, 2007, Expert opinion on pharmacotherapy.

Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation.

D. Nicolau, J. Kuti, Shawn H. MacVane, 2014, International journal of antimicrobial agents.

Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles

Su Young Lee, D. Nicolau, S. Y. Lee, 2012, Drugs.

Optimizing bactericidal exposure for β‐lactams using prolonged and continuous infusions in the pediatric population

Joshua D. Courter, D. Nicolau, Jennifer E. Girotto, 2009, Pediatric blood & cancer.

Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia

R. Ariano, D. Nicolau, Aryun Kim, 2009, Antimicrobial Agents and Chemotherapy.

Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance

D. Nicolau, J. Kuti, L. S. Filho, 2007 .

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit.

D. Nicolau, C. Mendes, C. Kiffer, 2007, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

D. Nicolau, J. Kuti, A. Dana, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Optimizing Antibiotic-Related Outcomes in the Critically Ill Patient

D. Nicolau, J. Kuti, 2005 .

In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Antimicrobial Agents and Chemotherapy.

Update on daptomycin: the first approved lipopeptide antibiotic

D. Nicolau, S. Y. Lee, J. Kuti, 2006, Expert opinion on pharmacotherapy.

Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic Fibrosis

C. Kloft, D. Nicolau, M. Muhlebach, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Target Attainment of Oral β-Lactams for the Empiric Treatment of Acute Otitis Media in Children

G. Doern, D. Nicolau, Jennifer E. Girotto, 2008, Paediatric drugs.

Probability of Achieving Requisite Pharmacodynamic Exposure for Oral β-Lactam Regimens against Haemophilus influenzae in Children

M. Pichichero, G. Doern, D. Nicolau, 2008, Paediatric drugs.

A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?

D. Nicolau, J. Kuti, Kristin E. Linder, 2021, Journal of pharmacy practice.

Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance

D. Nicolau, B. Capitano, J. Kuti, 2012, PharmacoEconomics.

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients

D. Nicolau, C. Nightingale, Chonghua Li, 2006, Journal of clinical pharmacology.

Role of pharmacodynamics in designing dosage regimens for beta-lactams.

D. Nicolau, S. Kotapati, C. Nightingale, 2003, Connecticut medicine.

Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.

D. Nicolau, C. Mendes, C. Kiffer, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure

D. Nicolau, J. Kuti, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Prevalence of Methicillin-Resistant Staphylococcus aureus Strains With Vancomycin Minimum Inhibitory Concentration 2 &mgr;g/mL in New York City Area Hospitals and Implications on Pharmacodynamic Target Attainment

D. Nicolau, Aryun Kim, G. Sakoulas, 2009 .

A Pharmacodynamic Simulation to Assess Tigecycline Efficacy for Hospital-Acquired Pneumonia Compared with Other Common Intravenous Antibiotics

D. Nicolau, M. Dowzicky, J. Kuti, 2008, Journal of chemotherapy.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

D. Nicolau, C. Nightingale, Chonghua Li, 2005, The Journal of antimicrobial chemotherapy.

Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance

D. Nicolau, M. Monogue, J. Kuti, 2016, Expert review of clinical pharmacology.

In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure

Y. Hamada, D. Nicolau, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

C. Kloft, M. Zeitlinger, J. Kuti, 2017, Clinical Pharmacokinetics.

Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Christina A. Sutherland, D. Nicolau, J. Kuti, 2009, Antimicrobial Agents and Chemotherapy.

Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?

D. Nicolau, Aryun Kim, J. Kuti, 2009, Surgical infections.

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

J. D. De Waele, Elizabeth G. Rhee, D. Nicolau, 2020, The Journal of antimicrobial chemotherapy.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

L. Saiman, D. Nicolau, N. Neu, 2015, Diagnostic microbiology and infectious disease.

Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.

D. Nicolau, J. Kuti, M. Hagihara, 2012, Diagnostic microbiology and infectious disease.

The Current State of Multidrug‐Resistant Gram‐Negative Bacilli in North America

D. Nicolau, Joseph L. Kuti, David P. Nicolau, 2008, Pharmacotherapy.

Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling

J. Kuti, Yuwei Shen, 2023, Expert opinion on drug metabolism & toxicology.

In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae

D. Nicolau, J. Kuti, M. Grupper, 2019, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

D. Nicolau, J. Kuti, Shawn H. MacVane, 2013, Antimicrobial Agents and Chemotherapy.

Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.

D. Nicolau, J. Kuti, 2015, International journal of antimicrobial agents.

Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man

J. Kuti, A. Berry, 2022, Frontiers in Pharmacology.

Monte Carlo Simulation Methodologies for β‐Lactam/β‐Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments

G. Stein, D. Nicolau, J. Kuti, 2020, Journal of clinical pharmacology.

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

D. Nicolau, J. Kuti, S. A. Almarzoky Abuhussain, 2018, Antimicrobial Agents and Chemotherapy.

Optimized Cefiderocol Exposures in a Successfully Treated Critically Ill Patient with Polymicrobial Stenotrophomonas maltophilia Bacteremia and Pneumonia Receiving Continuous Venovenous Hemodiafiltration.

D. Nicolau, J. Kuti, A. Fratoni, 2021, International journal of antimicrobial agents.

Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis

D. Nicolau, O. Serrano, J. Kuti, 2020, Antimicrobial Agents and Chemotherapy.

The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.

D. Nicolau, S. Kotapati, Erika C. Geissler, 2005, Intensive & critical care nursing.

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.

D. Nicolau, S. Kotapati, Erika C. Geissler, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Pharmacokinetics and Monte Carlo Simulations of Doripenem in Patients with Febrile Neutropenia

G. Stein, Apoorv Kalra, D. Nicolau, 2012, The Annals of pharmacotherapy.

Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.

M. Scheetz, J. Kuti, N. Rhodes, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of Doripenem in Infected Patients Treated Within and Outside the Intensive Care Unit

D. Nicolau, R. Quintiliani, J. Kuti, 2013, The Annals of pharmacotherapy.

in Moderately to Morbidly Obese Adults Pharmacokinetics of Intravenous Linezolid

D. Nicolau, P. Papasavas, J. Kuti, 2014 .

Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries

E. Drozd, J. Kuti, Dayo Jagun, 2015, Infectious diseases in clinical practice.

Impact of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study

D. Nicolau, S. Kotapati, S. Y. Lee, 2006, Infection Control & Hospital Epidemiology.

Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program.

D. Nicolau, J. Crandon, J. Kuti, 2009, International journal of antimicrobial agents.

Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model

D. Nicolau, J. Crandon, J. Kuti, 2010, Antimicrobial Agents and Chemotherapy.

Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

D. Nicolau, H. Huse, J. Kuti, 2021, Annals of Clinical Microbiology and Antimicrobials.

Optimizing Antibiotic Pharmacodynamics for Clinical Practice

D. Nicolau, J. Kuti, K. Connors, 2013 .

Comparison of 2002–2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance

Ronald N. Jones, D. Nicolau, J. Crandon, 2009, The Annals of pharmacotherapy.

Reply to Cheng and Chuang.

C. Arias, M. Weisser, D. Nicolau, 2019, Clinical Infectious Diseases.

Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Journal of Clinical Microbiology.

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Islam M. Ghazi, D. Nicolau, R. Quintiliani, 2016, International journal of antimicrobial agents.

Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2010, Diagnostic microbiology and infectious disease.

Pharmacodynamics of daptomycin when prescribed in combination with other antibiotics for treatment of enterococcal bacteremia.

C. Arias, M. Weisser, D. Nicolau, 2019, International journal of antimicrobial agents.

Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy.

D. Nicolau, J. Kuti, Larry A Suecof, 2011, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc.

Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

D. Nicolau, S. Barriere, J. Kuti, 2008, Pharmacotherapy.

Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

D. Nicolau, E. Salerno, J. Kuti, 2023, The Journal of antimicrobial chemotherapy.

Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.

D. Nicolau, A. Thabit, J. Kuti, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In vitro blood culture bottle inoculation of whole blood with clinically relevant antibiotic concentrations: a word of caution

D. Nicolau, J. Kuti, M. Grupper, 2017, European Journal of Clinical Microbiology & Infectious Diseases.

The Essential Role of Pharmacists in Antimicrobial Stewardship

Jason C. Gallagher, D. T. Bearden, J. Kuti, 2016, Infection Control & Hospital Epidemiology.

Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.

D. Nicolau, J. Kuti, Ana Motos, 2019, International journal of antimicrobial agents.

IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics

D. Nicolau, C. Nightingale, J. Kuti, 2004 .

Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem

D. Nicolau, Joseph L Kuti, Sheryl Horowitz, 2005, Pharmacotherapy.

1652. Sulbactam against Acinetobacter baumannii Pneumonia: Pharmacokinetic/Pharmacodynamic Appraisal of Current Dosing Recommendations

D. Nicolau, Kamilia Abdelraouf, J. Kuti, 2022, Open Forum Infectious Diseases.

Early Antibiotic Discontinuation in Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative Bronchoscopy Cultures*

D. Nicolau, M. Nailor, J. Kuti, 2013, Critical care medicine.

Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.

D. Nicolau, J. Kuti, K. Eagye, 2009, Seminars in respiratory and critical care medicine.

Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis

D. Nicolau, Ashley K. Shepard, J. Kuti, 2022, The Journal of antimicrobial chemotherapy.

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.

D. Nicolau, J. Kuti, D. Maglio, 2005, Clinical therapeutics.

Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.

D. Nicolau, Hui Wang, Y. Ni, 2007, International journal of antimicrobial agents.

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.

D. Nicolau, J. Kuti, C. Bulik, 2010, Clinical therapeutics.

Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins

D. Nicolau, J. Kuti, I. Chen, 2019, Journal of Clinical Microbiology.

Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

D. Nicolau, M. Nailor, J. Kuti, 2014, Scandinavian journal of infectious diseases.

Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model

D. Nicolau, J. Kuti, I. Chen, 2020, Antimicrobial Agents and Chemotherapy.

Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods

S. Jenkins, D. Nicolau, Catharine C. Bulik, 2010, Journal of Clinical Microbiology.

Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision.

D. Nicolau, J. Kuti, A. Fratoni, 2021, The Journal of antimicrobial chemotherapy.

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.

D. Nicolau, C. Nightingale, J. Kuti, 2004, Clinical therapeutics.

Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints.

D. Nicolau, J. Kuti, A. Fratoni, 2022, The Journal of antimicrobial chemotherapy.

Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit

D. Nicolau, J. Kuti, J. Gluck, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program

D. Nicolau, J. Kuti, Heather K. Sun, 2005, Critical care medicine.

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin

D. Nicolau, R. Quintiliani, A. Thabit, 2015, Infection Control & Hospital Epidemiology.

AAC 05473-11 Version 2 2 3 4 In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in 5 Combination against Methicillin-Resistant Staphylococcus aureus 6 7

D. Nicolau, D. Wiskirchen, J. Kuti, 2011 .

Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education

D. Nicolau, K. Keyloun, M. Nailor, 2018, Open forum infectious diseases.

Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).

D. Nicolau, J. Kuti, J. Gluck, 2022, International journal of antimicrobial agents.

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.

D. Nicolau, J. Kuti, Sergio Reyes, 2019, Clinical therapeutics.

Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2017, Clinical therapeutics.

Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.

D. Nicolau, J. Kuti, P. Tessier, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.

D. Nicolau, A. Thabit, J. Kuti, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model

A. Torres, D. Nicolau, J. Kuti, 2018, Antimicrobial Agents and Chemotherapy.

Empiric Treatment of Multidrug‐Resistant Burkholderia cepacia Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy

D. Nicolau, K. Moss, J. Kuti, 2004, Pharmacotherapy.

When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection.

D. Nicolau, J. Kuti, E. L. Gillespie, 2005, Connecticut medicine.

Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals.

D. Nicolau, D. Sahm, J. Kuti, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.

D. Nicolau, D. Melnick, J. Kuti, 2006, International journal of antimicrobial agents.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

D. Nicolau, M. Scheetz, Cristina M Miglis, 2017, International journal of antimicrobial agents.

Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections.

D. Nicolau, M. Dowzicky, J. Kuti, 2008, Surgical infections.

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.

G. Stein, D. Nicolau, D. Havlichek, 2019, Surgical infections.

Optimal Dosing of Piperacillin‐Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion?

Aryun Kim, Christina A. Sutherland, D. Nicolau, 2007, Pharmacotherapy.

Treatment of Serratia marcescens Meningitis with Prolonged Infusion of Meropenem

D. Nicolau, R. Quintiliani, J. Kuti, 2007, The Annals of pharmacotherapy.

Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.

D. Nicolau, J. Kuti, L. Maggio, 2017, Journal of clinical pharmacology.

Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2014, American Journal of Health-System Pharmacy.

The Use of Scoring Systems to Predict Prognosis in Patients With Ventilator-associated Pneumonia

D. Nicolau, D. Wiskirchen, J. Kuti, 2011 .

Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia

D. Nicolau, J. Kuti, C. Dempsey, 2021, Hospital pharmacy.

In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2009, Clinical therapeutics.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Jerome J. Schentag, M. Neely, G. Drusano, 2014, The Lancet. Infectious diseases.

Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization

D. Nicolau, J. Kuti, A. Kois, 2022, Open forum infectious diseases.

In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure

Y. Hamada, D. Nicolau, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure

D. Nicolau, J. Kuti, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.

D. Nicolau, G. Furtado, E. Medeiros, 2015, Revista da Sociedade Brasileira de Medicina Tropical.

Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa.

D. Nicolau, J. Kuti, C. A. Deryke, 2005, Connecticut medicine.

Treatment of Clostridium difficile-associated disease (CDAD).

D. Nicolau, C. Nightingale, J. Kuti, 2003, Connecticut medicine.

Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics.

D. Nicolau, J. Kuti, J. Aslanzadeh, 2008, Journal of medical microbiology.

A New Dosing Frontier: Retrospective Assessment of Effluent Flow Rates and Residual Renal Function Among Critically Ill Patients Receiving Continuous Renal Replacement Therapy

J. Kuti, Tomefa E. Asempa, Damini Lakshmipathy, 2024, Critical care explorations.

Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

D. Nicolau, S. Barriere, J. Kuti, 2008, Pharmacotherapy.

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.

D. Nicolau, S. Kotapati, J. Kuti, 2005, Surgical infections.

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral.

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.